Masimo Corporation (MASI)

Masimo Corporation manufactures and sells non-invasive patient-monitoring devices — instruments that measure vital signs like oxygen saturation and carbon dioxide levels without cutting into the skin. These sensors have become standard equipment in hospitals, surgical suites, and increasingly in consumer wearables. The company’s core business has been monitoring devices and the consumable sensors that go with them; its growth has come from expanding into new physiology measurements and into consumer health through partnerships like its technology in the Apple Watch. The company is based in Irvine, California, and operates globally, with revenue spread across hospitals and critical-care settings in developed markets and a growing presence in emerging regions.

The origins of pulse oximetry at scale

Joe Kiani founded Masimo in 1989 with a focus on improving pulse oximetry — a way to measure blood-oxygen saturation without needles. Traditional pulse oximeters of the era were unreliable during patient motion and in low-perfusion states, which limited their usefulness. Kiani’s insight was to apply signal processing to filter out artifact and noise, creating what became known as Signal Extraction Technology (SET). This approach allowed Masimo’s oximeters to read accurately even when patients were moving or had poor circulation — a real clinical advantage in critical care.

The company began by selling to hospitals in the United States and gradually expanded its footprint. The business model was clean: sell the monitor device once (or upgrade periodically), then sell disposable sensors repeatedly as long as the monitor was in use. That recurring consumable revenue — the sensors that attach to a patient’s finger or ear — became the engine of profitability, because the sensors have very high margins and customers have no economical alternative once they own a Masimo monitor.

Monitoring devices and sensors as the core engine

The bulk of Masimo’s revenue comes from its core monitoring business: patient monitors and their sensors. Hospitals and surgical centers use these monitors continuously in critical-care units, operating rooms, and recovery areas. Each monitor is a one-time capital purchase, typically several thousand dollars. But the sensors — the small probes that clip to a patient’s finger or stick to the skin — are consumable and replaced with every patient or several times per patient. That means a hospital that installs ten patient monitors will order sensors in volume for years, and the margins on sensors are substantially higher than on the hardware itself.

The monitors evolved over the years to add more capability: besides oxygen saturation, Masimo began measuring end-tidal carbon dioxide (the CO2 a patient exhales), non-invasive blood pressure, and later brain activity via regional oxygen saturation (rSO2). This gave hospitals more reason to standardize on Masimo monitors and gave the company more revenue per installed device.

Expansion beyond critical care into consumer health

Masimo’s leap into consumer technology came through partnerships rather than direct consumer sales. The most visible is its relationship with Apple. Masimo’s technology powers the blood-oxygen sensor in the Apple Watch — a non-invasive measurement that millions of people now wear daily. This consumer exposure has raised Masimo’s profile but also creates a subtle tension: most of the company’s profit still comes from selling to hospitals, where margins are built into a different price architecture and relationship than consumer electronics.

The company has also pursued acquisitions to broaden its monitoring portfolio. It acquired Rad-97, expanding into capnography (end-tidal CO2 measurement). It built a patient-monitoring data platform called ConnectedCare to integrate with hospital IT systems. These moves stretched Masimo beyond pure devices into software and data services — a common trajectory for medical-device companies trying to build stickier customer relationships.

Profitability rooted in switching costs and installed base

Masimo’s competitive moat is partly the technology — its signal processing is genuinely better than older competitors — but mostly practical. A hospital that has installed Masimo monitors and trained staff to use them incurs real cost and disruption to switch to a different brand. Nurses become familiar with the interface; protocols are written around it; data integrations rely on Masimo’s signals. The installed base of monitors creates demand for sensors that is hard to erode, especially since sensors are not interchangeable across brands.

That installed-base dynamic means Masimo benefits from what economists call a “bind-in” — customers renew the relationship automatically by ordering supplies. This creates more predictable revenue streams than the monitor sales alone and allows the company to invest in research and development for new measurements and monitoring capabilities.

Competitive landscape and pressure from price

Masimo faces competition from established medical-device companies like Philips and GE Healthcare, which offer larger portfolios of hospital equipment and have long-standing relationships with hospital purchasing departments. These rivals can bundle monitoring with other gear and sometimes use price pressure to defend share. Newer entrants and regional players also compete on cost, especially in emerging markets where hospitals have smaller budgets.

The industry has also faced regulatory and reimbursement pressure. Hospital margins have compressed as payers squeeze reimbursement rates, and hospitals have become more price-conscious on monitoring equipment. Masimo’s premium-technology positioning is a strength in critical care, where patient safety is paramount, but less of an advantage in routine monitoring, where a cheaper, adequate alternative can win on cost.

The research and development story

Masimo invests substantially in R&D to expand its monitoring platform. Beyond oxygen and CO2, the company has worked on non-invasive measurements of hemoglobin, methemoglobin, carboxyhemoglobin, and even consciousness level via brain activity. Each new measurement creates an opportunity to upgrade existing installations and cross-sell into new customer segments.

The Apple Watch partnership has also shaped R&D priorities, as consumer-grade sensors must be smaller, faster, and more power-efficient than hospital monitors. This consumer-device work has occasionally introduced new technology back into the hospital business.

Understanding Masimo as an investment

Investors in Masimo tend to focus on three metrics. The first is the ratio of recurring sensor revenue to one-time device revenue — the higher the recurring portion, the more predictable and cash-generative the business. The second is the growth of the installed base of monitors in use, which forecasts future sensor demand. The third is the company’s ability to expand into adjacent measurements and geographies without sacrificing the margins that have made the core business profitable.

The company’s annual 10-K filing (SEC CIK 0000937556) details the revenue mix between devices and sensors and breaks down geographic exposure. Quarterly earnings calls often highlight new product launches and adoption metrics in key hospital systems. Tracking the growth of sensor revenue per monitor — and the velocity of new monitor placements in large health systems — offers a leading indicator of whether Masimo’s growth is sustainable or whether competitive pressure is eroding its position.

The business is inherently capital-light compared to manufacturing, since most production is outsourced, but it is research-intensive. Understanding the pipeline of new measurements Masimo is developing helps explain whether the company can continue justifying premium pricing or whether it will face commoditization in monitoring as technology advances.